Scancell Financial Year End 2025 Results
by chantal | Sep 11, 2025 | Investor Presentations, Investors, Presentations
Recent Posts
- Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma
- Active Immunotherapy: Ready For Prime Time
- Strategic transactions to unlock longer-term value
- Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
- iSCIB1+ pivotal trial plans advancing
Recent Comments
No comments to show.